GSK to leverage the Cell and Gene Therapy Catapult’s facility in Stevenage
British drugmaker to expand its clinical manufacturing capacity for cell and gene therapy
Read More
Tag: CGT Catapult
Rentschler Biopharma to build cell and gene therapy manufacturing capabilities in the UK
German CDMO will build new manufacturing capabilities at CGT Catapult site
Read More
Cell and Gene Therapy Catapult links with Japan’s CiRA Foundation
The groups will explore novel methods to characterise pluripotent stem cells for the manufacture of regenerative medicine products
Read More
UK surge in cell and gene therapy trials
A surge in cell and gene therapy trials – an increase of 37% since 2017 – highlights the UK’s leading position as a developmental hub in the sector, says the Cell and Gene Therapy Catapult.
Read More
Cell and Gene Therapy Catapult addresses sector skills gap
The Cell and Gene Therapy (CGT) Catapult has launched the first Advanced Therapy Medicinal Products (ATMP) focused apprenticeship programme, developed in partnership with The Medicine Manufacturing Industry Partnership (MMIP).
Read More
MHRA permits cell/gene therapy production at CGT Catapult site
The production of new cell and gene therapies at a manufacturing site in Stevenage – for use in health services around the world – has been given the green light by the Medicines and Healthcare products Regulatory Agency (MHRA).
Read More
CGT Catapult unveils major UK investment in skills and capabilities
The Cell and Gene Therapy Catapult (CGT Catapult) has announced a major investment in skills and capability training to help accelerate integration of cell and gene therapies into health services following their regulatory approval.
Read More
Cell and Gene Therapy Catapult forges stronger link with Japan
The UK’s Cell and Gene Therapy Catapult (CGT Catapult) is linking with the Japanese Society for Regenerative Medicine (JSRM) to propel progress in regenerative medicine and cell/gene therapies in both countries.
Read More
Rexgenero wins £1.4m grant from Innovate UK
London, UK-based Rexgenero has secured with partners £1.4 million in funding for a £1.8 million project from the UK’s innovation agency Innovate UK, for an industrial research project on the commercial manufacture of its product REX-001.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
